-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Castle Biosciences, Raises Price Target to $44

Benzinga·08/03/2026 10:35:41
Listen to the news
BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $40 to $44.